A Phase 2A Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF)

Grant

Date/time Interval

  • September 1, 2015 - August 31, 2016

    • Awarded By

    Total Award Amount

  • 20354.00

    • Direct Costs

  • 13846.00

    • Sponsor Award Id

  • 161118-STOP ALF

    • Contributor

  • Edwards, Adam L.   Investigator  
  • Massoud, Omar   Investigator  
  • McGuire, Brendan   Principal Investigator  
  • Shoreibah, Mohamed   Investigator